Stilla Technologies

Digital PCR (dPCR) technologies are powerful tools that can be adapted to a variety of specialized applications. This talk explores target multiplexing in qPCR and dPCR assays to maximize the potential of today’s PCR instruments.

Join us in this webinar as we discuss critical aspects for dye selection, address inter-assay dimer concerns, and compare singleplex with multiplex data to ensure assay compatibility. For more challenging targets, including multiplexing allelic discrimination assays, we will look closer at the advantages of IDT's Affinity Plus™ locked nucleic acid probes over conventional hydrolysis probes.

The second part of the webinar will focus on highly multiplexed dPCR assays using the new Stilla® naica® system for Crystal Digital PCR™. The naica® system is a complete digital PCR solution with flexible sample throughput and highly sensitive detection and quantification of target nucleic acids. The new Prism fluorescent scanner allows target detection in up to 6-color channels, enabling another exclusive dimension for multiplexed dPCR assays. We will also present data explaining SNP detection in liquid biopsy samples obtained using the naica dPCR instrument.

By Kimberley Gutierrez, Application Scientist Manager at
Stilla Technologies & Erik Wendlandt, Field Applications Scientist at Integrated DNA Technologies

Design and optimize high multiplexing digital PCR assays with the naica® system

- GMO detection & quantification using high multiplexing Crystal Digital PCR and tolerance to inhibitors
- Going further- our next innovation- 6-color Crystal Digital PCR

Benefits of Crystal Digital PCR™ for Environmental and Food Testing

-Single assay quantification of more than 90% of known EGFR mutations

-Reliable and rapid detection of common mutations found in breast cancer

-Rectal cancer panel to detect and quantify PIK3CA mutations

By Kimberley Gutierrez & Viviane Sternkopf, application specialists (Stilla Technologies)

Liquid biopsy Quantification using 6-color Multiplexing for Cancer Panels

The commercialization of digital PCR platforms has sparked a revolution in quantitative nucleic acid detection over the past decade. Stilla Technologies’ Naica System, an established easy-to-use digital PCR platform, offers an innovative solution that quantifies in three colors while minimizing time to results.

This webinar will present the features of the company’s new 6-color Crystal Digital PCR System and highlight a set of applications poised to greatly benefit from the increased multiplexing and high sensitivity of 6-color digital PCR.

First, Alexandra Bogozalec from the National Institute of Biology in Slovenia will detail how her team has capitalized on the high-plex capacity of 6-color Crystal Digital PCR to simplify the time-consuming GMO quantification workflow and simultaneously quantify a set of genetically modified soybean lines at low target concentrations.

This webinar will also discuss how the highly sensitive detection capability of 6-color Crystal Digital PCR benefits oncology applications. Allison Mallory of Stilla Technologies will present high-plex mutation detection in non-small cell lung cancer, colorectal and breast cancer samples and will show how 6-color digital PCR enables efficient therapeutic monitoring and early detection of treatment resistance through noninvasive liquid biopsy.

By Alexandra Bogozalec Kosir, Research Assistant at the National Institute of Biology (Slovenia) & Allison Mallory, Director of Molecular Biology R&D at Stilla Technologies.

Innovation in Digital PCR: Maximizing Data Output from Precious Samples

The current gold standard for COVID-19 diagnosis is based on the detection of SARS-CoV-2 nucleic acid using real-time quantitative PCR (RT-qPCR). Recent studies suggest limitations of RT-qPCR in the detection of SARS-CoV-2, possibly leading to false-negative results. Development of robust and sensitive laboratory tests is of primary importance. Naica™ System is a Digital PCR platform offering absolute quantification of nucleic acids withvery high sensitivity and precision. Based on early and successful proof of concept in China, Stilla is developing a SARS-CoV-2 detection kit on the Naica™ System: a highly sensitive and internally controlled SARS-CoV-2 3-plex. It allows detection of two distinct regions: Nucleocapside (N) and ORF1ab genes of the SARS-CoV-2 positive-strand RNA genome, and an endogenous PCR reference detecting a human housekeeping gene. 
This single assay design permits the simultaneous detection of two independent SARS-CoV-2 sequences while concurrently monitoring sample PCR effectiveness. Due to its higher sensitivity, Crystal Digital PCR coupled with the detection kit for SARS-CoV-2 should be a perfect alternative to investigate non-conclusive high Ct results obtained in RT-qPCR.

By Romain Parillaud, PhD, International Application Specialist, Stilla Technologies

Highly Sensitive Crystal Digital PCR™ Detection Kit for SARS-CoV-2

Stilla Technologies talk was broadcast at EMBL Virtual Symposium: The Four-Dimension Genome (30-31st of March, 2020). <br/>Alexandra Martin, PhD., Application Specialist at Stilla Technologies walks you through Stilla's Crystal Digital PCR™ technology and its applications using the Naica™ System

Stilla Technologies

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.